| Literature DB >> 29260031 |
Zuowei Duan1, Lihong Tao1, Tieyu Tang1, Changbiao Fu1, Jiangbing Liu1, Bin Chen1, Zhensheng Liu2, Haifeng Zhang1, Yihui Liu1, Xinjiang Zhang1.
Abstract
BACKGROUND ANDEntities:
Keywords: Blood pressure variability; Early neurological deterioration; Parental arterial disease; Single small subcortical infarct
Year: 2017 PMID: 29260031 PMCID: PMC5730913 DOI: 10.1016/j.ensci.2017.06.006
Source DB: PubMed Journal: eNeurologicalSci ISSN: 2405-6502
Fig. 1Example of SSSIPAD: a 67 years old man, END was occurred during the first 17 h after onset.
Fig. 2Example of SSSI without PAD: a 73 years old woman, whose clinical condition had not get worse during the first 72 h after onset.
Comparison between patients with END and those without according the status of parent artery.
| Characteristics | SSSI with PAD | SSSI without PAD | ||
|---|---|---|---|---|
| END (N = 30) | Non-END (N = 48) | END (N = 53) | Non-END (N = 165) | |
| General clinical characteristics | ||||
| Age, years, mean (SD) | 68.97 ± 9.18 | 62.46 ± 12.31 | 67.57 ± 12.03 | 63.47 ± 11.75 |
| Female, N (%) | 17 (56.7) | 16 (33.38) | 28 (52.8) | 49 (29.7) |
| Hypertension, N (%) | 18 (60.0) | 29 (60.4) | 33 (62.3) | 94 (57.0) |
| Diabetes mellitus, N (%) | 12 (40.0) | 10 (20.8) | 18 (34.0) | 24 (14.5) |
| Hyperlipidemia, N (%) | 9 (30.0) | 14 (29.2) | 14 (26.4) | 35 (21.2) |
| Ischemic heart disease, N (%) | 5 (16.7) | 8 (16.7) | 4 (7.5) | 18 (10.9) |
| Smoking, N (%) | 12 (40.0) | 15 (31.2) | 18 (34.0) | 59 (35.8) |
| Drinking, N (%) | 8 (26.7) | 12 (25.0) | 12 (22.6) | 38 (23.0) |
| Initial NIHSS, median (IQR) | 6 (4–9) | 5 (2–8) | 6 (3–8) | 4 (2–5) |
| Onset to initial MRI, hours, mean (SD) | 10.77 ± 4.32 | 11.06 ± 3.77 | 10.40 ± 4.35 | 10.18 ± 4.45 |
| Length-of-hospital stay, days, mean (SD) | 9.73 ± 3.81 | 8.85 ± 3.90 | 8.38 ± 3.07 | 7.55 ± 2.60 |
| Lesion diameter, mm, mean (SD) | 13.47 ± 4.46 | 11.48 ± 4.16 | 12.27 ± 2.66 | 11.01 ± 3.83 |
| LA (Fazekas scale ≥ 2), N (%) | 10 (33.3) | 19 (39.6) | 21 (39.6) | 69 (41.8) |
| ICAS, N (%) | 15 (50.0) | 11 (22.9) | 16 (30.2) | 28 (17.0) |
| ECAS, N (%) | 10 (33.3) | 9 (18.8) | 12 (22.6) | 24 (14.5) |
| WBC (× 109, | 7.57 ± 2.92 | 6.83 ± 2.12 | 7.65 ± 2.54 | 7.48 ± 2.20 |
| RBC (× 1012, | 4.54 ± 0.52 | 4.47 ± 0.62 | 4.41 ± 0.63 | 4.46 ± 0.58 |
| FBG (mmol/l, | 7.41 ± 3.48 | 6.69 ± 2.94 | 6.88 ± 2.86 | 5.88 ± 2.33 |
| CRP (mg/l, | 21.50 ± 13.12 | 13.97 ± 19.18 | 14.99 ± 27.53 | 8.28 ± 11.63 |
| Current medications | ||||
| Acute stain treatment, N (%) | 13 (43.3) | 26 (54.2) | 29 (54.7) | 90 (54.5) |
| Dual-antiplatelet therapy, N (%) | 10 (33.3) | 14 (29.2) | 16 (30.2) | 48 (29.1) |
| BP parameter | ||||
| SBP | ||||
| SBPmean | 144.59 ± 7.65 | 141.04 ± 9.8 | 142.34 ± 12.98 | 141.93 ± 9.35 |
| SBPmax | 189.30 ± 23.68 | 173.46 ± 17.49 | 180.15 ± 22.89 | 178.54 ± 22.06 |
| SBPmax–min | 76.07 ± 26.31 | 61.08 ± 16.60 | 67.51 ± 22.82 | 66.27 ± 24.07 |
| SBPSD | 17.36 ± 4.94 | 14.43 ± 3.22 | 16.43 ± 5.29 | 15.78 ± 5.25 |
| SBPCV | 12.27 ± 3.05 | 10.26 ± 2.35 | 11.53 ± 3.46 | 11.10 ± 3.60 |
| DBP | ||||
| DBPmean | 82.58 ± 4.45 | 80.64 ± 4.59 | 81.47 ± 5.69 | 81.20 ± 4.75 |
| DBPmax | 101.00 ± 8.39 | 94.10 ± 7.82 | 97.60 ± 7.41 | 97.44 ± 11.46 |
| DBPmax–min | 36.50 ± 15.47 | 28.79 ± 9.31 | 32.25 ± 8.61 | 32.64 ± 11.57 |
| DBPSD | 8.00 ± 2.18 | 6.86 ± 2.05 | 7.81 ± 2.10 | 7.78 ± 2.55 |
| DBPCV | 10.28 ± 2.66 | 8.56 ± 2.70 | 9.69 ± 2.99 | 9.56 ± 2.99 |
< 0.05.
< 0.1.
Multivariable analysis of the associations between BP parameters and the development of END as well as poor outcome at 90 days after onset.
| SSSI with PAD | END | Poor outcome | ||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| SBPmean | 1.068 (0.996–1.146) | 0.063 | 0.987 (0.919–1.061) | 0.724 |
| SBPmax | 1.036 (1.005–1.069) | 0.023 | 0.999 (0.966–1.033) | 0.947 |
| SBPmax–min | 1.027 (0.999–1.055) | 0.058 | 1.013 (0.983–1.045) | 0.405 |
| SBPSD | 1.177 (1.021–1.356) | 0.024 | 1.112 (0.959–1.290) | 0.160 |
| SBPCV | 1.306 (1.049–1.626) | 0.017 | 1.049 (0.823–1.338) | 0.698 |
| DBPmean | 1.136 (0.981–1.317) | 0.089 | 1.078 (0.914–1.272) | 0.370 |
| DBPmax | 1.141 (1.042–1.250) | 0.005 | 1.085 (0.997–1.182) | 0.059 |
| DBPmax–min | 1.085 (1.015–1.160) | 0.017 | 1.054 (1.000–1.111) | 0.051 |
| DBPSD | 1.369 (1.032–1.816) | 0.029 | 1.607 (1.147–2.253) | 0.006 |
| DBPCV | 1.281 (1.028–1.597) | 0.028 | 1.379 (1.059–1.795) | 0.017 |
Adjustment by age, sex, diabetes mellitus, baseline NIHSS, lesion diameter, CRP and ICAS.
Adjustment by age, sex, diabetes mellitus, baseline NIHSS, lesion diameter, ICAS, FBG and CRP.
Adjustment by age, diabetes mellitus, baseline NIHSS, lesion diameter.
Adjustment by age, sex, diabetes mellitus, baseline NIHSS, lesion diameter, Hyperlipidemia, CRP, FBGand ICAS.
Comparison between patients with poor outcome and those with good outcome at 90 days after onset based on the status of parent artery.
| Characteristics | SSSI with PAD | SSSI without PAD | ||
|---|---|---|---|---|
| Poor outcome (N = 16) | Good outcome (N = 62) | Poor outcome (N = 38) | Good outcome (N = 180) | |
| General clinical characteristics | ||||
| Age, years, mean (SD) | 69.81 ± 6.78 | 63.29 ± 10.97 | 67.92 ± 9.13 | 63.74 ± 12.33 |
| Female, N (%) | 8 (50.0) | 25 (40.3) | 20 (52.6) | 57 (31.3) |
| Hypertension, N (%) | 10 (62.5) | 37 (59.7) | 25 (65.8) | 102 (56.7) |
| Diabetes mellitus, N (%) | 8 (50.0) | 14 (22.6) | 12 (31.6) | 30 (16.7) |
| Hyperlipidemia, N (%) | 5 (31.2) | 18 (29.0) | 13 (34.2) | 36 (20.0) |
| Ischemic heart disease, N (%) | 4 (25.0) | 9 (14.5) | 4 (10.5) | 18 (10.0) |
| Smoking, N (%) | 4 (25.0) | 23 (37.1) | 16 (42.1) | 61 (33.9) |
| Drinking, N (%) | 6 (37.5) | 14 (22.6) | 9 (23.1) | 41 (22.8) |
| Initial NIHSS, median (IQR) | 8 (6–12) | 6 (3–8) | 7 (4–9) | 4 (2–5) |
| Onset to initial MRI, hours, mean (SD) | 10.75 ± 3.32 | 11.10 ± 3.85 | 10.37 ± 4.37 | 10.20 ± 4.44 |
| Length-of-hospital stay, days, mean (SD) | 9.50 ± 4.43 | 9.11 ± 3.74 | 7.95 ± 2.71 | 7.71 ± 2.75 |
| Lesion diameter, mm, mean (SD) | 12.56 ± 4.83 | 12.17 ± 4.27 | 13.37 ± 3.09 | 10.88 ± 3.58 |
| LA (Fazekas scale ≥ 2), N (%) | 8 (50.0) | 21 (33.9) | 12 (31.6) | 78 (43.3) |
| ICAS, N (%) | 5 (31.2) | 21 (33.9) | 14 (36.8) | 30 (16.7) |
| ECAS, N (%) | 5 (31.2) | 14 (22.6) | 5 (13.2) | 31 (17.2) |
| WBC (× 109, | 7.05 ± 2.22 | 7.13 ± 2.54 | 7.93 ± 2.65 | 7.43 ± 2.19 |
| RBC (× 1012, | 4.70 ± 0.56 | 4.44 ± 0.58 | 4.39 ± 0.67 | 4.46 ± 0.57 |
| FBG (mmol/l, | 7.25 ± 3.38 | 6.89 ± 3.13 | 7.09 ± 2.85 | 5.92 ± 2.37 |
| CRP (mg/l, | 19.62 ± 24.55 | 16.15 ± 15.22 | 18.75 ± 31.15 | 8.04 ± 11.56 |
| Current medications | ||||
| Acute stain treatment N (%) | 7 (43.8) | 32 (51.6) | 17 (44.7) | 102 (56.7) |
| Dual-antiplatelet therapy, N (%) | 7 (43.8) | 17 (27.4) | 10 (26.3) | 54 (30.0) |
| BP parameter | ||||
| SBP | ||||
| SBPmean | 141.54 ± 6.93 | 142.63 ± 9.68 | 142.61 ± 10.90 | 141.91 ± 10.22 |
| SBPmax | 183.88 ± 15.71 | 178.44 ± 22.61 | 182.03 ± 22.48 | 178.28 ± 22.18 |
| SBPmax–min | 75.88 ± 18.22 | 64.52 ± 22.38 | 69.74 ± 19.55 | 65.91 ± 24.51 |
| SBPSD | 17.25 ± 2.30 | 14.44 ± 4.23 | 16.90 ± 4.77 | 15.73 ± 5.35 |
| SBPCV | 11.80 ± 2.74 | 10.84 ± 2.80 | 11.82 ± 3.12 | 11.07 ± 3.64 |
| DBP | ||||
| DBPmean | 82.76 ± 4.05 | 81.03 ± 4.70 | 81.92 ± 4.66 | 81.12 ± 5.05 |
| DBPmax | 100.75 ± 10.61 | 95.73 ± 7.87 | 9.39 ± 8.06 | 97.28 ± 11.08 |
| DBPmax–min | 37.25 ± 9.39 | 30.34 ± 12.92 | 32.68 ± 9.47 | 32.51 ± 11.21 |
| DBPSD | 8.74 ± 2.30 | 6.93 ± 1.98 | 7.88 ± 2.03 | 7.76 ± 2.53 |
| DBPCV | 10.84 ± 2.73 | 8.80 ± 2.68 | 9.70 ± 2.88 | 9.57 ± 3.01 |
| END, N (%) | 10 (62.5) | 20 (32.3) | 28 (73.3) | 10 (13.9) |
< 0.05.
< 0.1.